MediciNova, Inc. (MNOV): Price and Financial Metrics


MediciNova, Inc. (MNOV): $2.07

0.12 (+6.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNOV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNOV Stock Price Chart Interactive Chart >

Price chart for MNOV

MNOV Price/Volume Stats

Current price $2.07 52-week high $3.18
Prev. close $1.95 52-week low $1.89
Day low $1.98 Volume 21,581
Day high $2.10 Avg. volume 28,330
50-day MA $2.32 Dividend yield N/A
200-day MA $2.30 Market Cap 101.53M

MediciNova, Inc. (MNOV) Company Bio


MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. The company was founded in 2000 and is based in La Jolla, California.


MNOV Latest News Stream


Event/Time News Detail
Loading, please wait...

MNOV Latest Social Stream


Loading social stream, please wait...

View Full MNOV Social Stream

Latest MNOV News From Around the Web

Below are the latest news stories about MEDICINOVA INC that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast)

Yahoo | March 9, 2023

MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update GBM Trial Fully Enrolled On January 12, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced that the Phase 2 trial of MN-166 (ibudilast) in combination with temozolomide (TMZ) for the treatment of glioblastoma (GBM) is fully enrolled ( NCT03782415 ). This is a two-part trial taking place at Dana-Farber Cancer Institute;

Yahoo | February 27, 2023

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

LA JOLLA, Calif., Feb. 20, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia, PhD, Scientific Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at Cleveland Clinic and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Ca

Yahoo | February 20, 2023

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

LA JOLLA, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the l

Yahoo | February 8, 2023

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

LA JOLLA, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2b clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD) has completed enrollment. This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The NIAAA R01 research funding

Yahoo | January 30, 2023

Read More 'MNOV' Stories Here

MNOV Price Returns

1-mo -11.16%
3-mo -6.76%
6-mo -4.17%
1-year -19.46%
3-year -30.54%
5-year -83.05%
YTD 0.98%
2022 -23.51%
2021 -49.05%
2020 -21.96%
2019 -17.50%
2018 26.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6959 seconds.